Table A2a. Categories of adverse events (AEs).
Placebo (n=40) | 0.8 g LT-02 (n=40) | 1.6 g LT-02 (n=41) | 3.2 g LT-02 (n=35) | ||
---|---|---|---|---|---|
Any pretreatment AE | n (%) | 5 (12.5%) | 6 (15.0%) | 8 (19.5%) | 3 (8.6%) |
Any treatment-emergent AE | n (%) | 22 (55.0%) | 25 (62.5%) | 20 (48.8%) | 17 (48.6%) |
Any posttreatment AE | n (%) | 7 (17.5%) | 8 (20.0%) | 7 (17.1%) | 6 (17.1%) |
Any adverse drug reaction (ADR) | n (%) | 6 (15.0%) | 5 (12.5%) | 3 (7.3%) | 4 (11.4%) |
Any serious adverse event (SAE) | n (%) | 4 (10.0%) | 5 (12.5%) | 2 (4.9%) | 1 (2.9%) |
Any treatment-emergent SAE | n (%) | 4 (10.0%) | 4 (10.0%) | 2 (4.9%) | 0 |
Any potentially study medication-induced SAE | n (%) | 1 (2.5%) | 0 | 0 | 0 |